Factors to Consider in the Treatment of Early Relapsed/Refractory Multiple Myeloma
Sikander Ailawadhi, MD
Accredited Activity
Immunotherapeutic Strategies in RRMM: Differentiating Between Emerging Approaches
Irene Ghobrial, MD
Accredited Activity
Recent Advances Made in Myeloma Treatment
Joshua Richter, MD, and Ajai Chari, MD
Accredited Activity
Recent Activities by Topic
- VIDEO: Practice Essential - Optimizing Induction Therapy for Newly Diagnosed Multiple Myeloma: Navigating the Treatment Options - Ajay K. Nooka, MD, MPH, FACP
- eNewsletter - Changing Treatment Paradigms in Smoldering and NDMM - Jonathan L. Kaufman, MD
- VIDEO: FAQ - Lenalidomide-Related Diarrhea Correlates with Disease Control in Newly Diagnosed Patients with Multiple Myeloma - Beth Faiman, PnD, RN, MSN, APRN-BC, AOCN
- VIDEO: FAQ - Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed MM - Ajay K. Nooka, MD, MPH, FACP
- VIDEO: Practice Essential - Factors to Consider in the Treatment of Early Relapsed/Refractory Multiple Myeloma - Sikander Ailawadhi, MD
- VIDEO: Practice Essential - Immunotherapeutic Strategies in RRMM: Differentiating Between Emerging Approaches - Irene Ghobrial, MD
- VIDEO: FAQ - A Phase 1/2 Trial of Low-Dose Continuous Azacitidine in Combination with Lenalidomide and Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma - Beth Faiman, PnD, RN, MSN, APRN-BC, AOCN
- VIDEO: FAQ - Real-World Data on the Safety and Efficacy of Pomalidomide as a Single Agent and in Combination with Corticosteroids in Relapsed and Refractory Multiple Myeloma - Beth Faiman, PnD, RN, MSN, APRN-BC, AOCN